NCT00513968View on ClinicalTrials.gov

Phase I Study to Investigate the Safety and Efficacy of HBV DNA Vaccine

PHASE1CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

April 30, 2010

Study Completion Date

December 31, 2010

Conditions
Chronic Hepatitis B
Interventions
GENETIC

a mixed plasmid DNA (HB-110)

HB-110 2mg (or 4mg or 8mg), im, every other week, from week 0 to week 22 (total 12 injections) and Adefovir(Adefovir dipivoxil 10mg), od, from week -10 to from week 48.

DRUG

Adefovir

Adefovir(Adefovir dipivoxil)10mg, od, from week -10 to week 48.

Trial Locations (1)

137-701

Kangnam St. Mary's Hospital, Seoul

Sponsors

Lead Sponsor

Genexine, Inc.
All Listed Sponsors
lead

Genexine, Inc.

INDUSTRY

NCT00513968 - Phase I Study to Investigate the Safety and Efficacy of HBV DNA Vaccine | Biotech Hunter | Biotech Hunter